Here is Why Growth Investors Should Buy Masimo (MASI) Now

Zacks recommends medical technology company Masimo (MASI) as a strong growth pick, assigning it an 'A' Growth Score and a #2 Zacks Rank. This recommendation is driven by Masimo's projected annual EPS growth of 17.9%, which surpasses the industry average of 14.8%, and its robust 13% year-over-year cash flow growth, contrasting sharply with the industry's -2.5%. Additionally, positive earnings estimate revisions, including a 7% surge in current-year estimates over the last month, further support the view that Masimo is a potential outperformer for growth investors.

Analysis

Masimo (MASI) presents a strong growth profile according to a proprietary analysis by Zacks, which has assigned the company a Growth Score of 'A' and a Zacks Rank of #2 (Buy). This positive outlook is substantiated by several key financial metrics that outperform industry averages. The company's earnings per share (EPS) are projected to grow 17.9% this year, exceeding the medical technology industry's average forecast of 14.8%. Furthermore, Masimo demonstrates robust financial health through its cash flow, with year-over-year growth of 13%, a stark contrast to the industry's average decline of 2.5%. This is supported by a solid historical annualized cash flow growth rate of 10.7% over the past 3-5 years, compared to the industry's 6.3%. The bullish sentiment is further reinforced by recent positive earnings estimate revisions, with the Zacks Consensus Estimate for the current year surging 7% over the last month, a factor empirically correlated with near-term stock performance.

Key Decisions for Investors

• Given the combination of a top Zacks Rank, superior projected EPS growth, and robust cash flow generation relative to its industry, growth-oriented investors should consider MASI a fundamentally strong candidate for a long position.
• Investors should monitor upcoming earnings reports to ensure the company's performance validates the projected 17.9% EPS growth and maintains its strong cash flow momentum, as these are the core pillars of the current investment thesis.
• While the outlook is positive, investors must remain cognizant of the inherent volatility associated with growth stocks and should watch for any negative shifts in analyst earnings estimates, which could signal a change in the company's near-term prospects.